to a polypeptide complex the polypeptide complex may comprise a dendritic cell binding protein and a polypeptide antigen but preferably the polypeptide antigen is either a tissue specific tumor antigen or an oncogene gene product however it is appreciated that other antigens such as viral antigens can be used in such combination to produce immunostimulatory responses in another preferred embodiment the dendritic cell binding protein that forms part of the immunostimulatory polypeptide complex is gm csf in a further preferred embodiment the polypeptide antigen that forms part of the complex is the tumor specific antigen prostatic acid phosphatase in still other preferred embodiments the polypeptide antigen may be any one of the oncogene product peptide antigens the polypeptide complex may also contain between the dendritic cell binding protein and the polypeptide antigen a linker peptide the polypeptide complex may comprise a dendritic cell binding protein covalently linked to a polypeptide antigen such polypeptide complex being preferably formed from a dendritic cell binding protein preferably gm csf and a polypeptide antigen the polypeptide antigen is preferably a tissue specific tumor antigen such as prostatic acid phosphatase pap or an oncogene product such as her2 p21ras and p53 however other embodiments such as viral antigens are also within the scope of the invention the term.